[company_age]16.0[/company_age][employees]101-250 employees[/employees][funding]seed[/funding][description]ImmunoLogix is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer and infectious diseases. The company's lead product candidate, IMX-110, is a novel, first-in-class, anti-CD47 antibody that is currently being evaluated in multiple Phase 2 clinical trials for the treatment of various types of cancer. ImmunoLogix is headquartered in Waltham, Massachusetts, and has a research and development facility in Houston, Texas. The company's proprietary technology platform is based on the use of humanized antibodies and small molecules to modulate the immune system. ImmunoLogix's approach is differentiated by its focus on targeting the CD47 pathway, which is a novel and promising approach to cancer immunotherapy. The company's lead product candidate, IMX-110, has demonstrated promising preclinical and clinical activity, and has the potential to be a best-in-class anti-CD47 antibody. ImmunoLogix is also developing a pipeline of other immunotherapies, including IMX-120, a fully human monoclonal antibody that targets the OX40 receptor on T cells, and IMX-310, a novel small molecule that inhibits the NLRP3 inflammasome.[/description][ps]ImmunoLogix develops innovative therapies for cancer and infectious diseases.[/ps]